vs
Esperion Therapeutics, Inc.（ESPR）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$179.7M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 35.7%），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
ESPR vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出108.0%
35.7%
两年增速更快
RKLB
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $179.7M |
| 净利润 | — | $-52.9M |
| 毛利率 | — | 38.0% |
| 营业利润率 | 50.6% | -28.4% |
| 净利率 | — | -29.5% |
| 营收同比 | 143.7% | 35.7% |
| 净利润同比 | — | -1.1% |
| 每股收益（稀释后） | $0.32 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRRKLB
| Q4 25 | $168.4M | $179.7M | ||
| Q3 25 | $87.3M | $155.1M | ||
| Q2 25 | $82.4M | $144.5M | ||
| Q1 25 | $65.0M | $122.6M | ||
| Q4 24 | $69.1M | $132.4M | ||
| Q3 24 | $51.6M | $104.8M | ||
| Q2 24 | $73.8M | $106.3M | ||
| Q1 24 | $137.7M | $92.8M |
净利润ESPRRKLB
| Q4 25 | — | $-52.9M | ||
| Q3 25 | $-31.3M | $-18.3M | ||
| Q2 25 | $-12.7M | $-66.4M | ||
| Q1 25 | $-40.5M | $-60.6M | ||
| Q4 24 | — | $-52.3M | ||
| Q3 24 | $-29.5M | $-51.9M | ||
| Q2 24 | $-61.9M | $-41.6M | ||
| Q1 24 | $61.0M | $-44.3M |
毛利率ESPRRKLB
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.6% | ||
| Q1 24 | — | 26.1% |
营业利润率ESPRRKLB
| Q4 25 | 50.6% | -28.4% | ||
| Q3 25 | -11.4% | -38.0% | ||
| Q2 25 | 8.6% | -41.3% | ||
| Q1 25 | -34.0% | -48.3% | ||
| Q4 24 | -6.4% | -38.9% | ||
| Q3 24 | -31.0% | -49.5% | ||
| Q2 24 | 3.5% | -40.7% | ||
| Q1 24 | 52.5% | -46.4% |
净利率ESPRRKLB
| Q4 25 | — | -29.5% | ||
| Q3 25 | -35.9% | -11.8% | ||
| Q2 25 | -15.4% | -46.0% | ||
| Q1 25 | -62.2% | -49.5% | ||
| Q4 24 | — | -39.5% | ||
| Q3 24 | -57.2% | -49.6% | ||
| Q2 24 | -83.9% | -39.2% | ||
| Q1 24 | 44.3% | -47.7% |
每股收益（稀释后）ESPRRKLB
| Q4 25 | $0.32 | $-0.09 | ||
| Q3 25 | $-0.16 | $-0.03 | ||
| Q2 25 | $-0.06 | $-0.13 | ||
| Q1 25 | $-0.21 | $-0.12 | ||
| Q4 24 | $-0.14 | $-0.11 | ||
| Q3 24 | $-0.15 | $-0.10 | ||
| Q2 24 | $-0.33 | $-0.08 | ||
| Q1 24 | $0.34 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $-302.0M | $1.7B |
| 总资产 | $465.9M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资ESPRRKLB
| Q4 25 | $167.9M | $1.0B | ||
| Q3 25 | $92.4M | $976.7M | ||
| Q2 25 | $86.1M | $688.1M | ||
| Q1 25 | $114.6M | $428.4M | ||
| Q4 24 | $144.8M | $419.0M | ||
| Q3 24 | $144.7M | $442.4M | ||
| Q2 24 | $189.3M | $496.8M | ||
| Q1 24 | $226.6M | $492.5M |
总债务ESPRRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益ESPRRKLB
| Q4 25 | $-302.0M | $1.7B | ||
| Q3 25 | $-451.4M | $1.3B | ||
| Q2 25 | $-433.5M | $688.5M | ||
| Q1 25 | $-426.2M | $431.3M | ||
| Q4 24 | $-388.7M | $382.5M | ||
| Q3 24 | $-370.2M | $419.8M | ||
| Q2 24 | $-344.2M | $455.2M | ||
| Q1 24 | $-294.3M | $478.9M |
总资产ESPRRKLB
| Q4 25 | $465.9M | $2.3B | ||
| Q3 25 | $364.0M | $2.2B | ||
| Q2 25 | $347.1M | $1.6B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | $1.2B | ||
| Q3 24 | $314.1M | $1.2B | ||
| Q2 24 | $352.3M | $1.2B | ||
| Q1 24 | $373.1M | $1.2B |
负债/权益比ESPRRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-114.2M |
| 自由现金流率自由现金流/营收 | — | -63.6% |
| 资本支出强度资本支出/营收 | 0.0% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-321.8M |
8季度趋势，按日历期对齐
经营现金流ESPRRKLB
| Q4 25 | $45.2M | $-64.5M | ||
| Q3 25 | $-4.3M | $-23.5M | ||
| Q2 25 | $-31.4M | $-23.2M | ||
| Q1 25 | $-22.6M | $-54.2M | ||
| Q4 24 | $-35.0M | $-2.4M | ||
| Q3 24 | $-35.3M | $-30.9M | ||
| Q2 24 | $-7.2M | $-13.0M | ||
| Q1 24 | $53.8M | $-2.6M |
自由现金流ESPRRKLB
| Q4 25 | — | $-114.2M | ||
| Q3 25 | — | $-69.4M | ||
| Q2 25 | — | $-55.3M | ||
| Q1 25 | — | $-82.9M | ||
| Q4 24 | — | $-23.9M | ||
| Q3 24 | $-35.5M | $-41.9M | ||
| Q2 24 | $-7.3M | $-28.3M | ||
| Q1 24 | $53.8M | $-21.8M |
自由现金流率ESPRRKLB
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -44.8% | ||
| Q2 25 | — | -38.3% | ||
| Q1 25 | — | -67.6% | ||
| Q4 24 | — | -18.1% | ||
| Q3 24 | -68.7% | -40.0% | ||
| Q2 24 | -9.9% | -26.7% | ||
| Q1 24 | 39.0% | -23.5% |
资本支出强度ESPRRKLB
| Q4 25 | 0.0% | 27.6% | ||
| Q3 25 | 0.0% | 29.6% | ||
| Q2 25 | 0.0% | 22.2% | ||
| Q1 25 | 0.0% | 23.4% | ||
| Q4 24 | 0.0% | 16.3% | ||
| Q3 24 | 0.3% | 10.5% | ||
| Q2 24 | 0.1% | 14.4% | ||
| Q1 24 | 0.1% | 20.7% |
现金转化率ESPRRKLB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
